CN110810851B - 一种基于食品材料组装肠道释放IgG微胶囊及其制备方法 - Google Patents
一种基于食品材料组装肠道释放IgG微胶囊及其制备方法 Download PDFInfo
- Publication number
- CN110810851B CN110810851B CN201810918927.1A CN201810918927A CN110810851B CN 110810851 B CN110810851 B CN 110810851B CN 201810918927 A CN201810918927 A CN 201810918927A CN 110810851 B CN110810851 B CN 110810851B
- Authority
- CN
- China
- Prior art keywords
- igg
- microcapsule
- solution
- bsa
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 48
- 239000000463 material Substances 0.000 title claims abstract description 40
- 235000013305 food Nutrition 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000000968 intestinal effect Effects 0.000 title abstract description 11
- 229940027941 immunoglobulin g Drugs 0.000 claims abstract description 63
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 34
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 26
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 26
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 25
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 25
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 25
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 25
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 25
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 25
- 229940033123 tannic acid Drugs 0.000 claims abstract description 25
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 25
- 229920002258 tannic acid Polymers 0.000 claims abstract description 25
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 18
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 17
- 239000001110 calcium chloride Substances 0.000 claims abstract description 17
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 17
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 17
- 238000004925 denaturation Methods 0.000 claims abstract description 11
- 230000036425 denaturation Effects 0.000 claims abstract description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 11
- 210000004051 gastric juice Anatomy 0.000 claims abstract description 9
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 8
- 238000011068 loading method Methods 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 6
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- DWVBTGTYJNNGSW-MMNCBLCDSA-N C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O.C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O Chemical compound C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O.C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(\C=C\C1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O DWVBTGTYJNNGSW-MMNCBLCDSA-N 0.000 claims abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 20
- 239000004005 microsphere Substances 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 108010039918 Polylysine Proteins 0.000 claims description 9
- 229920000656 polylysine Polymers 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims 1
- 235000013365 dairy product Nutrition 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 description 8
- 239000011859 microparticle Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- UFCLZKMFXSILNL-AALYGJCLSA-N 3,4-Dicaffeoylquinic acid Natural products O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@](O)(C(=O)O)C[C@@H]1O)/C=C/c1cc(O)c(O)cc1 UFCLZKMFXSILNL-AALYGJCLSA-N 0.000 description 6
- UFCLZKMFXSILNL-BKUKFAEQSA-N 3,4-di-O-caffeoylquinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O UFCLZKMFXSILNL-BKUKFAEQSA-N 0.000 description 6
- UFCLZKMFXSILNL-PSEXTPKNSA-N Isochlorogenic acid b Chemical compound O([C@@H]1C[C@@](O)(C[C@H]([C@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-PSEXTPKNSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了一种基于食品材料组装肠道释放IgG微胶囊及其制备方法,涉及食品加工技术领域。所述肠道定向释放自组装微胶囊,所用原料为牛血清蛋白(BSA)、表没食子儿茶素没食子酸酯(EGCG)、3,4‑二咖啡酰奎尼酸(3,4‑diCQA)、单宁酸(TA)和免疫球蛋白G(IgG)、氯化钙、碳酸钠和EDTA等。本发明克服了现有技术的不足,采用天然食品原料BSA作为基底,以3种功能性食品多酚原料为桥连剂,依次加入后优化得到蛋白‑多酚IgG微胶囊。所得微胶囊IgG负载率达5.7%,该胶囊在胃液中稳定,在肠道中释放,热变性温度提高至78℃,缓释抗氧化时间大于24h,此微胶囊有效的保护了IgG在乳品生产加工及肠道定向释放后的生物活性,对IgG的进一步实际应用具有重要意义。
Description
技术领域
本发明涉及食品加工技术领域,具体涉及一种基于食品材料组装肠道释放IgG微胶囊及其制备方法。
背景技术
免疫球蛋白G(IgG)作为牛初乳中含量最高的免疫球蛋白(占总免疫球蛋白的80~86%),其主要功能是中和毒素、病毒、与细菌结合及免疫调节的作用,然而热、酸、酶等都会影响IgG的活性:乳品加工过程中不可避免地要进行灭菌或巴氏杀菌、蒸发浓缩及喷雾干燥等工艺,IgG在75℃会发生严重热变性,当免疫球蛋白添加到食品中时其活性不可避免地受到热处理的影响;在低酸性(pH<2)下IgG的活性将会严重丧失,而且胃蛋白酶也将完整IgG分解为无生物活性的片段F(ab)2′和pFc′,因此,应当从酸、热及胃蛋白酶方面防止免疫球蛋白的变性从而保持其免疫活性。
层层自组装(Layer-by-layer self-assembly,LBL)技术是利用逐层交替沉积的方法,借助各层分子间的相互作用力使层与层之间自发缔合形成结构完整、性能稳定、具有某种特定功能的分子聚集体或超分子结构的过程。然而层层自组装的缺点是使用的交联剂不仅昂贵而且多为具有高度细胞毒性的聚阳离子,并不适应于食品。此外,常见的层层自组装微胶囊大多仅使用一种交联剂,并未赋予微胶囊更多的功能及生物活性。
发明内容
针对现有技术不足,本发明提供一种基于食品材料组装肠道释放IgG微胶囊及其制备方法,克服了现有技术的不足,采用牛血清蛋白(BSA)、表没食子儿茶素没食子酸酯(EGCG)、3,4-二咖啡酰奎尼酸(3,4-diCQA)、单宁酸(TA)和免疫球蛋白G(IgG)为主料,聚赖氨酸盐酸盐(PLL)、氯化钙、碳酸钠和EDTA为辅料,获得包裹IgG微胶囊。该胶囊IgG负载率达高达5.7%,在胃液中稳定,在肠道中定向释放,并且热变性温度提高至78℃,缓释抗氧化时间大于24h,此微胶囊可控释的应用范围广泛,有效的保护了IgG在乳品生产加工及肠道定向释放后的生物活性,对IgG的进一步实际应用具有重要意义。
为实现以上目的,本发明的技术方案通过以下技术方案予以实现:
一种基于食品材料组装肠道释放IgG微胶囊,所用原料分为主料和辅料,其中主料为牛血清蛋白(BSA)、表没食子儿茶素没食子酸酯(EGCG)、3,4-二咖啡酰奎尼酸(3,4-diCQA)、单宁酸(TA)和免疫球蛋白G(IgG);辅料为聚赖氨酸盐酸盐(PLL)、氯化钙、碳酸钠和EDTA。
所述主料中各成分物质的量份数为IgG 2-3份、BSA 1-2份、EGCG 4-5份、3,4-diCQA 12-14份、TA 86-88份。
所述辅料配制浓度为0.4M碳酸钠、0.4M氯化钙、2mg/mL PLL和0.2M EDTA。
制作方法,第一步、首先将0.6mL 0.4M碳酸钠和0.8mL 4mg/mL IgG溶液混匀,而后加入0.6mL 0.4M氯化钙,剧烈搅拌30s,静置2min。随后13000r/min离心1min,收集沉淀并用水洗净,制得包封了IgG的碳酸钙微球。
第二步,取新制备的碳酸钙微粒浸入5mL的2mg/mL PLL溶液以产生第一锚定层,连续摇动15min后,通过13000r/min离心1min收集微粒,通过用去离子水洗涤两次除去残留的PLL。
第三步,加入BSA和3种多酚(依次按EGCG、3,4-diCQA、TA的顺序加入)的交替层,每次加入5mL 2mg/mL的相应溶液,加入之后进行洗涤步骤。重复该过程以获得(IgG-CaCO3)-(BSA-多酚)n微球。
第四步,将制备好的(IgG-CaCO3)-(BSA-多酚)n微球滴加到0.2M的EDTA溶液中(pH7.0),混合悬浮震荡一段时间,溶液由白色逐渐变得澄清,当溶液的颜色不再变化时,再经纯水在5000r/min下离心10min,重复洗涤3次,即得内含IgG空心微胶囊。
所得微胶囊在胃液中稳定,在肠道中定向释放。
所得微胶囊热变性温度提高至78℃。
所得微胶囊缓释抗氧化时间大于24h。
所得微胶囊IgG负载率高达5.7%。
本发明提供一种基于食品材料组装肠道释放IgG微胶囊及其制备方法,与现有技术相比优点在于:
本发明采用采用牛血清蛋白(BSA)、表没食子儿茶素没食子酸酯(EGCG)、3,4-二咖啡酰奎尼酸(3,4-diCQA)、单宁酸(TA)和免疫球蛋白G(IgG)为主料,聚赖氨酸盐酸盐(PLL)、氯化钙、碳酸钠和EDTA为辅料,获得包裹IgG微胶囊。该胶囊IgG负载率达高达5.7%,在胃液中稳定,在肠道中定向释放,并且热变性温度提高至78℃,缓释抗氧化时间大于24h,此微胶囊可控释的应用范围广泛,有效的保护了IgG在乳品生产加工及肠道定向释放后的生物活性,对IgG的进一步实际应用具有重要意义。
附图说明
图1是微胶囊的合成及模拟体外消化过程
图2是模拟胃液消化后(A)及肠液消化后(B)、(C)的自组装外层膜AFM外观形态分析
图3是模拟胃液消化后(A)(A’)和肠液消化后(B)、(B’)自组装外层膜的剖面SEM外观形态分析
图4是模拟胃液消化后(A1、A2、A3)和肠液消化后(B1、B2、B3)的微胶囊SEM外观形态分析
图5是微胶囊热变性温度分析
图6是微胶囊缓释抗氧化分析
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面结合本发明实施例对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1,一种基于食品材料组装肠道释放IgG微胶囊,所用原料分为主料和辅料,其中主料为牛血清蛋白(BSA)、表没食子儿茶素没食子酸酯(EGCG)、3,4-二咖啡酰奎尼酸(3,4-diCQA)、单宁酸(TA)和免疫球蛋白G(IgG);辅料为聚赖氨酸盐酸盐(PLL)、氯化钙、碳酸钠和EDTA。
所述主料中各成分物质的量份数为IgG 3份、BSA 1份、EGCG 4份、3,4-diCQA 13份、TA 87份。
所述辅料配制浓度为0.4M碳酸钠、0.4M氯化钙、2mg/mL PLL和0.2M EDTA。
制作方法,第一步、首先将0.6mL 0.4M碳酸钠和0.8mL 4mg/mL IgG溶液混匀,而后加入0.6mL 0.4M氯化钙,剧烈搅拌30s,静置2min。随后13000r/min离心1min,收集沉淀并用水洗净,制得包封了IgG的碳酸钙微球。
第二步,取新制备的碳酸钙微粒浸入5mL的2mg/mL PLL溶液以产生第一锚定层,连续摇动14min后,通过13000r/min离心1min收集微粒,通过用去离子水洗涤两次除去残留的PLL。
第三步,加入BSA和3种多酚(依次按EGCG、3,4-diCQA、TA的顺序加入)的交替层,每次加入5mL 2mg/mL的相应溶液,加入之后进行洗涤步骤。重复该过程以获得(IgG-CaCO3)-(BSA-多酚)n微球。
第四步,将制备好的(IgG-CaCO3)-(BSA-多酚)n微球滴加到0.2M的EDTA溶液中(pH7.0),混合悬浮震荡一段时间,溶液由白色逐渐变得澄清,当溶液的颜色不再变化时,再经纯水在5000r/min下离心10min,重复洗涤3次,即得内含IgG空心微胶囊。
所得微胶囊在胃液中稳定,在肠道中定向释放,热变性温度提高至78.3℃,抗氧化时间为25h,IgG负载率高达5.9%。
实施例2,一种基于食品材料组装肠道释放IgG微胶囊,所用原料分为主料和辅料,其中主料为牛血清蛋白(BSA)、表没食子儿茶素没食子酸酯(EGCG)、3,4-二咖啡酰奎尼酸(3,4-diCQA)、单宁酸(TA)和免疫球蛋白G(IgG);辅料为聚赖氨酸盐酸盐(PLL)、氯化钙、碳酸钠和EDTA。
所述主料中各成分物质的量份数为IgG 3份、BSA 2份、EGCG 5份、3,4-diCQA 14份、TA 87份。
所述辅料配制浓度为0.4M碳酸钠、0.4M氯化钙、2mg/mL PLL和0.2M EDTA。
制作方法,第一步、首先将0.6mL 0.4M碳酸钠和0.8mL 4mg/mL IgG溶液混匀,而后加入0.6mL 0.4M氯化钙,剧烈搅拌30s,静置2min。随后13000r/min离心1min,收集沉淀并用水洗净,制得包封了IgG的碳酸钙微球。
第二步,取新制备的碳酸钙微粒浸入5mL的2mg/mL PLL溶液以产生第一锚定层,连续摇动14min后,通过13000r/min离心1min收集微粒,通过用去离子水洗涤两次除去残留的PLL。
第三步,加入BSA和3种多酚(依次按EGCG、3,4-diCQA、TA的顺序加入)的交替层,每次加入5mL 2mg/mL的相应溶液,加入之后进行洗涤步骤。重复该过程以获得(IgG-CaCO3)-(BSA-多酚)n微球。
第四步,将制备好的(IgG-CaCO3)-(BSA-多酚)n微球滴加到0.2M的EDTA溶液中(pH7.0),混合悬浮震荡一段时间,溶液由白色逐渐变得澄清,当溶液的颜色不再变化时,再经纯水在5000r/min下离心10min,重复洗涤3次,即得内含IgG空心微胶囊。
所得微胶囊在胃液中稳定,在肠道中定向释放,热变性温度提高至78.5℃,抗氧化时间为24.5h,IgG负载率高达5.8%。
实施例3,一种基于食品材料组装肠道释放IgG微胶囊,所用原料分为主料和辅料,其中主料为牛血清蛋白(BSA)、表没食子儿茶素没食子酸酯(EGCG)、3,4-二咖啡酰奎尼酸(3,4-diCQA)、单宁酸(TA)和免疫球蛋白G(IgG);辅料为聚赖氨酸盐酸盐(PLL)、氯化钙、碳酸钠和EDTA。
所述主料中各成分物质的量份数为IgG 2份、BSA 1份、EGCG 4份、3,4-diCQA 15份、TA 88份。
所述辅料配制浓度为0.4M碳酸钠、0.4M氯化钙、2mg/mL PLL和0.2M EDTA。
制作方法,第一步、首先将0.6mL 0.4M碳酸钠和0.8mL 4mg/mL IgG溶液混匀,而后加入0.6mL 0.4M氯化钙,剧烈搅拌30s,静置2min。随后13000r/min离心1min,收集沉淀并用水洗净,制得包封了IgG的碳酸钙微球。
第二步,取新制备的碳酸钙微粒浸入5mL的2mg/mL PLL溶液以产生第一锚定层,连续摇动14min后,通过13000r/min离心1min收集微粒,通过用去离子水洗涤两次除去残留的PLL。
第三步,加入BSA和3种多酚(依次按EGCG、3,4-diCQA、TA的顺序加入)的交替层,每次加入5mL 2mg/mL的相应溶液,加入之后进行洗涤步骤。重复该过程以获得(IgG-CaCO3)-(BSA-多酚)n微球。
第四步,将制备好的(IgG-CaCO3)-(BSA-多酚)n微球滴加到0.2M的EDTA溶液中(pH7.0),混合悬浮震荡一段时间,溶液由白色逐渐变得澄清,当溶液的颜色不再变化时,再经纯水在5000r/min下离心10min,重复洗涤3次,即得内含IgG空心微胶囊。
所得微胶囊在胃液中稳定,在肠道中定向释放,热变性温度提高至78.6℃,抗氧化时间为24.7h,IgG负载率高达5.7%。
Claims (5)
1.一种基于食品材料组装肠道释放IgG微胶囊,其特征在于:所用原料分为主料和辅料,其中主料为牛血清蛋白 (BSA)、表没食子儿茶素没食子酸酯 (EGCG)、3,4-二咖啡酰奎尼酸(3,4-diCQA)、单宁酸 (TA)和免疫球蛋白G (IgG);辅料为聚赖氨酸盐酸盐、氯化钙、碳酸钠和EDTA;
所述微胶囊的制作方法为:
第一步、首先将0.6 mL 0.4 M 碳酸钠和 0.8 mL 4 mg/mL IgG 溶液混匀,而后加入0.6 mL 0.4 M 氯化钙,剧烈搅拌30s,静置2 min,随后13000 r/min离心1 min,收集沉淀并用水洗净,制得包封了IgG的碳酸钙微球;
第二步,取新制备的碳酸钙微球浸入5 mL的2 mg/mL聚赖氨酸盐酸盐溶液以产生第一锚定层,连续摇动15 min后,通过13000 r/min离心1 min收集微粒,通过用去离子水洗涤两次除去残留的聚赖氨酸盐酸盐;
第三步,加入BSA和依次按EGCG、3,4-diCQA、TA的顺序加入形成的3种多酚交替层,每次加入5 mL 2 mg/mL的相应溶液,加入之后进行洗涤步骤,重复该过程以获得(IgG-CaCO3)-(BSA-多酚)n微球;
第四步,将制备好的(IgG-CaCO3)-(BSA-多酚)n微球滴加到0.2 M的EDTA溶液中,且EDTA溶液的pH值为7.0,混合悬浮震荡一段时间,溶液由白色逐渐变得澄清,当溶液的颜色不再变化时,再经纯水在5000 r/min下离心10min,重复洗涤3次,即得内含IgG空心微胶囊。
2.根据权利要求1所述的微胶囊的制作方法,其特征在于:所得微胶囊在胃液中稳定,在肠道中定向释放。
3.根据权利要求1所述的微胶囊的制作方法,其特征在于:所得微胶囊热变性温度提高至78℃。
4.根据权利要求1所述的微胶囊的制作方法,其特征在于:所得微胶囊缓释抗氧化时间大于24h。
5.根据权利要求1所述的微胶囊的制作方法,其特征在于:所得微胶囊IgG负载率高达5.7%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810918927.1A CN110810851B (zh) | 2018-08-08 | 2018-08-08 | 一种基于食品材料组装肠道释放IgG微胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810918927.1A CN110810851B (zh) | 2018-08-08 | 2018-08-08 | 一种基于食品材料组装肠道释放IgG微胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110810851A CN110810851A (zh) | 2020-02-21 |
CN110810851B true CN110810851B (zh) | 2023-05-30 |
Family
ID=69546902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810918927.1A Active CN110810851B (zh) | 2018-08-08 | 2018-08-08 | 一种基于食品材料组装肠道释放IgG微胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110810851B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116172115B (zh) * | 2022-12-05 | 2024-05-14 | 西北农林科技大学 | 通过添加L-Lys改善高剂量EGCG对肉蛋白凝胶特性损伤的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104288123B (zh) * | 2014-10-27 | 2016-09-14 | 浙江理工大学 | 一种负载干扰素微胶囊的制备方法 |
CN105435722A (zh) * | 2015-12-29 | 2016-03-30 | 东华大学 | 一种聚l-乳酸和聚d-乳酸构成的聚乳酸中空微胶囊的制备方法 |
CN108451924B (zh) * | 2017-12-13 | 2020-03-27 | 温州生物材料与工程研究所 | 一步吸附法制备蛋白质微胶囊的方法 |
CN108246214B (zh) * | 2017-12-13 | 2021-02-09 | 温州生物材料与工程研究所 | 一步吸附法制备多肽微胶囊的方法 |
-
2018
- 2018-08-08 CN CN201810918927.1A patent/CN110810851B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110810851A (zh) | 2020-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4970678B2 (ja) | 多層コーティングによる結晶のカプセル化 | |
CN108451924B (zh) | 一步吸附法制备蛋白质微胶囊的方法 | |
Sakai et al. | Cell-enclosing gelatin-based microcapsule production for tissue engineering using a microfluidic flow-focusing system | |
CN110810851B (zh) | 一种基于食品材料组装肠道释放IgG微胶囊及其制备方法 | |
Chen et al. | Optimal thermotolerance of Bifidobacterium bifidum in gellan–alginate microparticles | |
JPH10512141A (ja) | 温水魚類ゼラチンを使用して食品又はフレーバ粒子をカプセル化する方法、およびその方法で製造したカプセル | |
JPS61189218A (ja) | カプセル封入方法 | |
Mohammadi et al. | Development of caffeine‐encapsulated alginate‐based matrix combined with different natural biopolymers, and evaluation of release in simulated mouth conditions | |
CN110547452A (zh) | 一种明胶-海藻酸钠复凝聚原花青素微胶囊的制备方法 | |
CN102217671A (zh) | 1-甲基环丙烯缓释剂及其制备方法 | |
CN101815507A (zh) | 微粒子、血液代用品及其形成方法 | |
JPS6038111B2 (ja) | 固定依存性細胞の培養法 | |
CN105238098A (zh) | 一种紫玉米芯花色苷动态梯度包埋方法 | |
CN109232920A (zh) | 鱼明胶/海藻酸钠双网络复合水凝胶、其制备方法及所得益生菌微胶囊 | |
Morales-Medina et al. | Structure, controlled release mechanisms and health benefits of pectins as an encapsulation material for bioactive food components | |
CA2214088A1 (en) | Novel encapsulation process by a gelling polymer | |
CN107252132B (zh) | 酪蛋白-卡拉胶自主装纳米微胶囊的制备方法及其应用 | |
CN110904029B (zh) | 一种单个哺乳动物细胞纳米封装方法及所得封装细胞 | |
CN113208111A (zh) | 一种复合壁材的甜菜红素微胶囊的制备方法 | |
He et al. | Alginate-casein microspheres as bioactive vehicles for nutrients | |
Meng et al. | Joint protection strategies for Saccharomyces boulardii: exogenous encapsulation and endogenous biofilm structure | |
CN109463526B (zh) | 一种促小麦蛋白高效脱酰胺降敏的方法 | |
Sakai et al. | Permeability of alginate/sol–gel synthesized aminopropyl-silicate/alginate membrane templated by calcium-alginate gel | |
CN102524762A (zh) | 一种营养物质凝胶粒及其生产方法 | |
Borodina et al. | Entrapment of herbal extracts into biodegradable microcapsules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |